James Nanney
Family Medicine · Meridian, MSNPI 1932181740
Payments from drug & device makers
Across 357 payments — averaging $11.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$705
- AbbVie$487
- Lilly USA, LLC$417
- Merck$390
- Amgen$307
- AstraZeneca$290
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,065100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $705 |
| AbbVie(2 entities) | 60 | $487 |
| Lilly USA, LLC | 41 | $417 |
| Merck | 32 | $390 |
| Amgen | 21 | $307 |
| AstraZeneca | 16 | $290 |
| GSK | 24 | $289 |
| Boehringer Ingelheim | 12 | $185 |
| Teva Pharmaceuticals USA, Inc. | 8 | $131 |
| Kowa Pharmaceuticals America, Inc. | 7 | $113 |
| Otsuka America Pharmaceutical, Inc. | 7 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $91 |
| Biohaven Pharmaceuticals, Inc. | 5 | $91 |
| Johnson & Johnson | 4 | $70 |
| Bayer | 4 | $67 |
| Pfizer | 4 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Amarin Pharma, Inc. | 2 | $40 |
| Mylan Specialty L.p. | 3 | $39 |
| Astellas Pharma US Inc | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Novartis | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$4,074 in reported general payments places this provider in the 80th percentile of 971 family medicine providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 187 | $195,810 |
| OzempicSemaglutide | 150 | $193,988 |
| FarxigaDapagliflozin Propanediol | 108 | $111,950 |
| EliquisApixaban | 102 | $100,437 |
| MounjaroTirzepatide | 94 | $100,366 |
| TrulicityDulaglutide | 72 | $88,446 |
| LinzessLinaclotide | 82 | $73,241 |
| RybelsusSemaglutide | 46 | $68,630 |
| XareltoRivaroxaban | 67 | $57,885 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $49,169 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $23,047 |
| VraylarCariprazine Hcl | 15 | $20,660 |
| MyrbetriqMirabegron | 22 | $19,486 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $16,955 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $705 | $262,617196 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Glyxambi | $185 | $218,575229 claims |
| Lilly USA, LLCMounjaro, Trulicity | $417 | $188,812166 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $290 | $126,051140 claims |
| PfizerEliquis | $56 | $100,437102 claims |
| AbbVieLinzess, Vraylar | $487 | $93,90197 claims |
| Johnson & JohnsonXarelto | $70 | $57,88567 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta, Arexvy | $289 | $44,159118 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $19,48622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Meridian
- Douglas PhillipsMeridian$11K
- Shawn AndersonMeridian$10K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.